Mustang Bio Inc
mustangbio.comWhat Do They Do?
Develops licensed cell and gene therapies for solid tumors, including CAR T cells and an oncolytic virus, with research institutions as partners.
10-K for FY2025, filed Mar 19, 2026Mustang Bio, Inc. (“Mustang,” “we,” “us,” “our” or the “Company”) is a clinical-stage biopharmaceutical company focused on translating…View ↗
Our pipeline is currently focused on novel therapies for solid tumors. For these therapies we have partnered with world class research…View ↗
Our pipeline is being developed under exclusive licenses from two world class research institutions. Our strategy is to license these…View ↗
We are developing a CAR T therapy for solid tumors in partnership with COH targeting IL13Rα2 (MB-101). In addition, we have partnered with…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 19, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 5, 2026
−$1.1MView ↗
- ▲ +41% (Loss)
- vs −$762K in Q2 FY2025
-
Apr 17, 2026
Nasdaq notified Mustang of a minimum bid-price deficiency
The company has until October 12, 2026, to regain compliance; the notice has no immediate effect on its Nasdaq listing.
Sources
8-K, filed Apr 17, 2026
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was afforded a 180-calendar day grace period, or until October 12, 2026, to…View ↗
Narrower therapy focus
The older report described programs for blood cancers, solid tumors, and rare genetic disorders, while the latest report focuses on solid-tumor therapies.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 19, 2026Mustang Bio, Inc. (“Mustang,” “we,” “us” or the “Company”) is a clinical-stage biopharmaceutical company focused on translating today’s…View ↗
Our pipeline is currently focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and…View ↗
In partnership with St. Jude, our XSCID gene therapy programs (MB-107 and MB-207) are being conducted under an exclusive license to develop…View ↗
Who Do They Compete With?
Competes with Gilead Sciences and ImmunityBio
10-K for FY2025, filed Mar 19, 2026The field of cellular therapy – including CAR T and CAR NK cell therapies – for the treatment of cancer is extremely active. We are aware…View ↗
Loading...
